Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of SIM0278 in active lupus nephritis
CTR20260349Phase 2Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Feb 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SIM0278 in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by Simcere Pharmaceutical Group. Started Feb 2026; status: active.
02
Drugs
SIM0278
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20260349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260349.